Harkness Pharmaceuticals

Harkness Pharmaceuticals is the multinational company Jack Harkness builds from the Swiss firm he acquires in the 1990s. Its blockbuster Elixtris makes it extraordinarily profitable and internationally influential, while the company’s products also become the delivery system for a concealed nanobot programme. The same expansion that turns Harkness Pharmaceuticals into a commercial giant therefore magnifies the consequences of its secrecy and the legal allegations against its leadership.

Formation and Corporate Expansion

Harkness’s route to control begins after an unexplained period away from public view. Between 1978 and 1981, he is largely off the grid; he later appears in Switzerland as personal assistant to Lenore Furgler, who has inherited control of Furgler Gesellschaft, a medium-sized pharmaceutical company based in Basel. During the 1980s, Harkness joins its board and takes responsibility for strategy, despite the distrust of other members of Furgler’s family.

In 1995, as Lenore’s health declines, she sells the company to Harkness. The sale price is described as neither especially high nor absurdly low, but the source of his purchase money remains uncertain. A reported possibility is a loan from Vladimir Drishkov, a Russian oligarch whose mining corporation was said to have been corruptly acquired; Drishkov is shot dead by unidentified assassins a few months later. The account does not resolve the financing question. What is clear is the change in control: the company becomes Harkness’s, and is renamed Harkness Pharmaceuticals.

Under Harkness, the business grows rapidly. He establishes a dedicated research laboratory in Locarno, where chief researcher Filippo Crosetti develops a succession of beauty products. The company’s expansion culminates in Elixtris, an anti-ageing cream released in 2009. It is credited with helping the company withstand the economic downturn and become a major global player. Harkness Pharmaceuticals also partners with Quintagler Industries to finance acquisitions that eliminate several middle-ranking competitors across North America, Europe, and Asia.

Products, Research, and Everyday Reach

Elixtris is both the company’s commercial breakthrough and a continuing source of public confidence in it. Even when allegations against Harkness depress the share price, analysts attribute a smaller-than-expected decline to the growing popularity of the Elixtris range. The product’s success is presented as so great that it helps make Harkness billions of pounds wealthy and turns the company into a formidable profit-maker.

The company’s reach extends beyond cosmetics. Its catalogue includes medicines such as Ditrimantelline and Fenextris, and its products enter ordinary domestic routines as well as specialist treatment. At Holly Walsh’s home, Elixtris face cream and body scrub sit alongside cartons of Ditrimantelline, a daily medication manufactured by Harkness Pharmaceuticals in Switzerland. Walsh has multiple sclerosis, and her account of living with the disease describes a costly experimental treatment as central to regaining control of her symptoms. The evidence connects her supply to an anonymous correspondent who says she works in pharmaceuticals and arranged the medicine after reading Walsh’s blogs; it does not establish that the company itself authorized or financed the supply.

That distinction matters because anonymous assistance leads investigators toward the company without immediately explaining who is responsible or why. Walsh receives money through the Nightingale account at Credit Suisse, and a man later approaches her to ask about it. He does not appear to be seeking information about Jane Glasson. The account’s funding and the anonymous supplier’s relationship to Harkness Pharmaceuticals remain part of the wider uncertainty surrounding the company’s money and influence.

Financial and Legal Allegations

The company’s commercial partnership with Quintagler Industries becomes the setting for serious accusations. Harkness dismisses the allegations as an attempt by Quintagler to take his company from him. The U.S. Department of Justice, however, says it has seen clear prima facie evidence of wrongdoing and is proceeding without regard to Quintagler’s commercial interests. The difference between Harkness’s account and the department’s stated position leaves the case unresolved in the public reporting, but makes clear that the matter is not presented simply as a private corporate dispute.

Quintagler alleges that Harkness diverted funds over several years through subsidiaries of shell companies that he ultimately owned. Those same companies are alleged to have been the source of bribes paid to doctors. The sums supposedly diverted exceed the amount attributed to bribery, while the destination of the rest remains unknown. The companies are based in tax havens with limited disclosure requirements, making the trail difficult to follow. The Nightingale account is described as a small, unusual exception to an otherwise opaque network rather than an explanation for the missing funds.

A separate U.S. case deepens the company’s exposure. Thirty-nine doctors are charged with taking Harkness Pharmaceuticals bribes to prescribe Fenextris for back, neck, and shoulder pain, although the drug is supposed to be reserved for cancer and other serious conditions because of its addictiveness. Medicare spending on Fenextris rises by 75 percent in a year, exceeding $280 million. One neurologist in Indianapolis is associated with $6.7 million in Fenextris prescriptions, pleads guilty, and agrees to cooperate with authorities. A company spokesperson denies bribing anyone. The reported charges thus connect corporate conduct not only to financial transfers but to prescribing practices and the public cost of medicine.

Secrecy Inside the Research Operation

The company’s research arrangements create a second, less visible layer of concern. Ingrid Denner’s inquiries to human resources produce increasingly detailed lists of current and former employees. Among them is retained specialist contractor number 55: a 46-year-old British woman attached to Crosetti’s staff. Human resources says it cannot provide personal information because Crosetti insists on absolute confidentiality for specialists he recruits himself. He supervises their work at the Locarno research facility and is solely responsible for them.

That unusual arrangement becomes relevant to the search for Jane Glasson. A file bearing her name connects an employee or contractor trail to work associated with Harkness Pharmaceuticals and Crosetti. Ingrid’s forthcoming meeting with Crosetti is to address both contraindications and specialist contractor 55. The company’s confidentiality rules, which place personally recruited specialists under Crosetti’s exclusive supervision, help explain why the employment trail is difficult to establish through ordinary human-resources channels.

Ingrid’s scrutiny also reaches beyond the identities of individual researchers. In an email concerning the Elixtris project, she questions the substantial budget assigned to outside scientists whose expertise is in nanotechnology and bioelectronics, fields that do not appear directly relevant to a conventional cosmetic. She arranges a meeting at the company’s headquarters in Zug and requests that subsequent communications go through her BlackBerry. At the meeting, she says the company has funded multiple research projects with no obvious connection to developing or improving pharmaceutical products. She also suspects that Crosetti has acted as a conduit for a vast additional package of funding with no recorded source, which she believes Harkness put in place.

Ingrid identifies three unresolved governance questions: why the funding is being handled so surreptitiously, why it has reached what appears to be a ruinous level of cost, and why the board has not been told about the project. The secrecy is not merely a matter of one protected contractor; it reaches budgets, funding sources, scientific recruitment, and board oversight.

The Nanobot Programme and Its Consequences

The hidden research is eventually explained as a nanobot programme designed to produce a result its participants believe the world needs. Harkness enters the pharmaceutical business because he considers it the means to achieve that result, and recruits Astrid Townsend and Crosetti into the work. The programme’s reach depends on the company’s ordinary commercial distribution: according to its disclosure, people who have used Harkness Pharmaceuticals drugs or cosmetics during the preceding five years have nanobots in their bloodstream. The same claim extends to people who have eaten food grown using the company’s pesticides or meat from animals treated with its antibiotics.

The list makes the scale of the scheme concrete. Beauty products, headache remedies, anti-malarials, painkillers, Elixtris, and Fenextris are all named as routes by which nanobots have been swallowed, injected, or absorbed through the skin. Millions of people are said to have been exposed. Harkness Pharmaceuticals’ diverse product range, previously the basis of its wealth and market power, becomes the infrastructure for distributing a technology beyond the company’s conventional medical and cosmetic purposes.

The company’s corporate headquarters in Zug reflects its scale: a large complex of blue steel and grey glass, built with water and trees around its towers. It is the setting for a confrontation over the supposedly irrelevant research, but the disclosures show that the central issue lies far beyond the building or its boardroom. The ordinary products on which the company’s success depends have made the concealed programme difficult to separate from its public business.

Crisis and Uncertain Aftermath

By the end of the account, Harkness is dead, and Crosetti has made sure the plan cannot work even if the panic room is opened. The company may still try to suppress what happened; the narrator considers that it could even succeed. A deal with Quintagler Industries and a large eventual fine are imagined as possible ways for the business to move on, while Astrid Townsend might be treated as a temporary consultant whose departure allows the company to distance itself from the affair. These are presented as expectations about how Harkness Pharmaceuticals may respond, not as confirmed outcomes.

The organization’s arc therefore turns on a stark reversal. Elixtris and global expansion make Harkness Pharmaceuticals seem almost immune to ordinary economic shocks, and the popularity of its products helps cushion the share-price damage of scandal. Yet that same reach allows the company’s secret programme to affect millions, while opaque financing and allegations of bribery undermine confidence in its governance. Harkness Pharmaceuticals is at once a successful manufacturer, a contested corporate power, and the instrument through which the hidden research acquires consequences on a mass scale.